Resverlogix Stock Price

TSX:RVXCA$14.2mPharmaceuticals & Biotech

RVX Share Price Performance

RVX Community Fair Values

View all narratives

Recent RVX News & Updates

No updates

Resverlogix Corp. Competitors

About RVX

Founded: n/a
Employees: n/a
CEO: Donald McCaffrey
WebsiteView website: www.resverlogix.com

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.

Resverlogix Corp. Key Details

Last Reported Earnings

Mar 31, 2025

Yearly revenue growth

n/a

Earnings per share (EPS): -0.049
Gross Margin: 0%
Net Profit Margin: 0%
Debt/Equity Ratio: -99.6%

View full report ›

Canadian Market Performance

7 Days: 1.4%
3 Months: 18.1%
1 Year: 19.9%
Year to Date: 8.8%

The market is up 1.4% over the last week, with the Materials sector leading the way, up 3.4%. In the last year, the market has climbed 20%. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›